Molecular pathogenesis and targets for therapy in myelodysplastic syndrome (MDS) and MDS-related leukemias

Current Opinion in Oncology

Volumn 10, Issue 1, 1998, Pages 3-9

  Karp, Judith E ^a  

^a UNIVERSITY OF MARYLAND MEDICAL SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ARYLBUTYRIC ACID DERIVATIVE; BUSULFAN; COLECALCIFEROL DERIVATIVE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTOKINE; DNA TOPOISOMERASE INHIBITOR; ERYTHROPOIETIN; GLYCOPROTEIN P; GRANULOCYTE COLONY STIMULATING FACTOR; INTERFERON; PROTEIN TYROSINE KINASE INHIBITOR; QUININE; RETINOID; STEM CELL FACTOR; TOPOTECAN; VALSPODAR; VERAPAMIL;

ACUTE GRANULOCYTIC LEUKEMIA; CANCER GENETICS; CELL CYCLE; CELL DIFFERENTIATION; CELL SURVIVAL; ENVIRONMENTAL EXPOSURE; GENE LOSS; GENE TRANSLOCATION; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL; HUMAN; MOLECULAR GENETICS; MULTIDRUG RESISTANCE; MYELODYSPLASTIC SYNDROME; OCCUPATIONAL EXPOSURE; ONCOGENE; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; STEM CELL TRANSPLANTATION;

EID: 0031964585     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-199801000-00002     Document Type: Review

References (48)

1. Bartram CR: Molecular genetic aspects of myelodysplastic syndromes. Semin Hematol 1996, 33:139-149.
2. Karp JE, Smith MA: The molecular pathogenesis of treatment-induced (secondary) leukemlas: foundations for treatment and prevention. Semin Oncol 1997, 24:103-113.
3. Pedersen Bjergaard J, Pedersen M, Roulston D, Philip P: Different genetic pathways In leukemogenesis for patients presenting with therapy-related myelodysplasia and therapy-related acute myeloid leukemia. Blood 1995, 86:3542-3552.
4. Fairman J, Wang RY, Liang H, Zhao L, Saltman D, Liang JC, Nagarajan L: Translocations and deletions of 5q13.1 in myelodysplasia and acute myelogenous leukemia: evidence for a novel critical locus. Blood 1996, 88:2259-2266.
5. Horrigan SK, Westbrook CA, Kim AH, Banerjee M, Stock W, Larson RA: Polymerase chain reaction-based diagnosis of del(5q) in acute myeloid leukemia and myelodysplastic syndrome identifies a minimal deletion interval. Blood 1996, 88:2665-2670.
6. Luna-Fineman S, Shannon KM, Lange BJ: Childhood monosomy 7: epidemiology, biology and mechanistic implications. Blood 1995, 85:1985-1999.
7. Fischer K, Frohling S, Scherer SW, Brown JM, Scholl C, Stilgenbauer S, Tsui L-C, Lichter P, Dohner H: Molecular cytogenetic delineation of deletions and translocations involving chromosome band 7q22 in myeloid leukemias. Blood 1997, 89:2036-2041.
8. Johnson EJ, Scherer SW, Osborne L, Tsui LC, Oscier D, Mould S, Cotter FE: Molecular definition of a narrow interval at 7q22.1 associated with myelodysplasla. Blood 1996, 87:3579-3586.
9. Le Beau MM, Espinosa R III, Davis EM, Eisenbart JD, Larson RA, Green ED: Cytogenetic and molecular delineation of a region of chromosome 7 commonly deleted in malignant myeloid diseases. Blood 1996, 88:1930-1935.
10. Hoglund M, Johansson B, Pedersen-Bjergaard J, Maynen P, Mitelman F: Molecular characterization of 12p abnormalities in hematologic malignancies: deletion of KIP1, rearrangement of TEL, and amplification of CCND2. Blood 1996, 87:324-330.
11. Sato Y, Suto Y, Pietenpol J, Golub TR, Gilliland DG, Davis EM, LeBeau MM, Roberts JM, Vogelstein B, Rowley JD, et al.: TEL and K1P1 define the smallest region of deletions on 12p13 in hematopoietic malignancies. Blood 1995, 86:1525-1533.
12. Kuefer MU, Look AT, Williams DC, Valentine V, Naeve CW, Behm FG, Mullersman JE, Yoneda-Kato N, Montgomery K, Kucherlapati R, et al.: cDNA cloning, tissue distribution, and chromosomal localization of myelodysplasia/myeloid leukemia factor 2 (MLF2). Genomics 1996, 53:392-396.
13. Yoneda-Kato N, Look AT, Kirstein MN, Valentine MB, Raimondi SC, Cohen KJ, Carroll AJ, Morris SW: The t(3;5)(q25.1;q34) of myelodysplastic syndrome and acute myeloid leukemia produces a novel fusion gene, NPM-MLF-1. Oncogene 1996, 12:265-275.
14. Wlodarska I, Mecucci C, Marynen P, Guo C, Franckx D, LaStarza R, Aventin A, Bosly A, Martelli MF, Cassiman JJ, Van den Berghe H: TEL gene is involved in myelodysplastic syndromes with either the typical t(5;12)(q33;p13) translocation or its variant t(10;12)(q24;p13). Blood 1995, 85:2848-2852.
15. Raynaud SD, Baens M, Grosgeorge J, Rodgers K, Reid CDL, Dainton M, Dyer M, Fuzibet JG, Gratecos N, Tailan B, Ayraud N, Marynen P: Fluorescence in situ hybridization analysis of t(3;12)(q26;p13): a recurring chromosomal abnormality involving the TEL gene (ETV6) in myelodysplastic syndromes. Blood 1996, 88:682-689.
16. Ben-Yehuda D, Krichevsky S, Caspi O, Rund D, Polliack A, Abeliovich D, Zelig O, Yahalom V, Paltiel O, Or R, et al.: Microsatellite instability and p53 mutations in therapy-related leukemia suggest mutator phenotype. Blood 1996, 88:4296-4303.
17. Tanaka N, Ishihara M, Lamphier MS, Nozawa H, Matsuyama T, Mak TW, Aizawa S, Tokino T, Oren M, Taniguchi T: Cooperation of the tumor suppressors IRF-1 and p53 in response to DNA damage. Nature 1996, 382:816-818.
18. Thorn J, Molloy P, Iland H: SSCP detection of N-ras promoter mutations in AML patients. Exp Hematol 1995, 23:1098-1103.
19. Bollag G, Clapp DW, Shih S, Adler F, Zhang YY, Thompson P, Lange BJ, Freedman MH, McCormick F, et al.: Loss of NF1 results in activation of the Ras signaling pathway and leads to aberrant growth in hematopoietic cells. Nat Genet 1996, 12:144-148.
20. Kohl NE, Omer CA, Conner MW, Anthony NJ, Davide JP, deSolms SJ, Giuliani EA, Gomez P, Graham SL, Hamilton K, et al.: Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice. Nature Med 1995, 1:792-797.
21. Mundle SD, Venugopal P, Cartlidge JD, Pandav DV, Broady-Robinson L, Gezer S, Robin EL, Rifkin SR, Klein M, Alston DE, et al.: Indication of an involvement of IL-1B converting enzyme-like protease in intramedullary apoptotic cell death in the bone marrow of patients with myelodysplastic syndromes. Blood 1996, 88:2640-2647.
22. Rajapaska R, Ginzyon N, Rott LS, Greenberg PL: Altered oncoprotein expression and apoptosis in myelodysplastic syndrome marrow cells. Blood 1996, 88:4275-4287.
23. Raza A, Alvi S, Broady-Robinson L, Showel M, Cartlidge J, Mundle, S, Shetty VT, Borok RZ, Dar SE, Chopra HK, et al.: Cell cycle kinetic studies in 68 patients with myelodysplastic syndromes following intravenous iodo-and/or bromodeoxyuridine. Exp Hematol 1997, 25:530-535.
24. Hoefsloot LH, van Amelsvoort MP, Breeders CAM, van der Ras DC, van Lom K, Hoogerbruggee H, Touw IP, Lowenberg B: Erythropoletin-induced activation of STAT5 is impaired in the myelodysplastic syndromes. Blood 1997, 89:1690-1700.
25. Ogata K, An E, Kamijubo K, Tamura H, Yokose N, Dan K, Nomura T: Cell cycle modulation by hematopoietic growth factors in myelodysplastic syndromes: analysis by three-color flow cytometry. Exp Hematol 1997, 25:8-18.
26. + cells. Blood 1996, 88:319-327.
27. Bouscary D, Preudhomme C, Ribrag V, Melle J, Viguie F, Picard F, Guesnu M, Fenaux P, Gisselbrecht S, Dreyfus F: Prognostic value of c-mpl expression in myelodysplastic syndromes. Leukemia 1995, 9:783-788.
28. Wetzler M, Baer MR, Bernstein SH, Blumenson L, Stewart C, Barcos M, Mrozek K, Block AMW, Herzig GP, Bloomfield CD: Expression of c-mpl mRNA, the receptor for thrombopoietin, in acute myeloid leukemia a group of patients with poor response to Intensive chemotherapy. J Clin Oncol 1997, 15:2262-2268.
29. Uchida N, Combs J, Chen S, Zanjani E, Hoffman R, Tsukamoto A: Primitive human hematopoietic cells displaying differential afflux of the rhodamine 123 dye have distinct biological activities. Blood 1996, 88:1297-1305.
30. Leith CP, Chen I-M, Kopecky KJ, Appelbaum FR, Head DR, Godwin JE, Weick JK, Willman CL: Correlation of multidrug resistance (MDRD protein expression with functional dye/drug afflux in acute myeloid leukemia by multiparameter flow cytometry: Identification of discordant MDR-/efflux+ and MDR1+/efflux- cases. Blood 1995, 86:2329-2342.
31. Haase D, Feuring-Buske M, Konemann S, Fonatsch C, Troff C, Verbeek W, Pekrun A, Hiddemann W, Wormann B: Evidence for malignant transformation in acute myeloid leukemia at the level of early hematopoietic stem cells by cytogenetic analysis of CD34+ subpopulations. Blood 1995, 86:2906-2912.
32. Mehrotra B, George TI, Kavanau K, Avet-Loiseau H, Moore D II, Willman CL, Slovak ML, Atwater S, Head DR, Pallavicini MG: Cytogenetically aberrant cells in the stem cell compartment (CD34+lin-) in acute myeloid leukemia. Blood 1995, 86:1139-1147.
33. Leith CP, Kopecky KJ, Godwin J, McConnell T, Slovak ML, Chen I-M, Head DR, Appelbaum FR, Willman CL: Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetlcs distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. Blood 1997, 89:3323-3329.
34. Kornblau SM, Estey E, Madden T, Tran HT, Zhao S, Consoli U, Snell V, Sanchez-Williams G, Kantarjian H, Keating M, et al.: Phase I study of mitoxantrone plus etoposide with multidrug blockade by SDZ PSC-833 in relapsed or refractory acute myelogenous leukemia. J Clin Oncol 1997, 15:1796-1802.
35. Solary E, Witz B, Caillot D, Moreau P, Desablens B, Cahn JY, Sadoun A, Pignon B, Berthou C, Maloisel F, et al.: Combination of quinine as a potential reversing agent with mitoxantrone and cytarabine for the treatment of acute leukemias: a randomized multicenter study. Blood 1996, 88:1198-1205.
36. Negrin RS, Stein R, Doherty K, Cornwell J, Vardiman J, Krantz S, Greenberg PL: Maintenance treatment of the anemia of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor and erythropoietin: evidence for in vivo synergy. Blood 1996, 87:4076-4081.
37. Raelson JV, Nervi C, Rosenauer A, Benedetti L, Monczak Y, Pearson M, Pelicci PG, Miller WH Jr: The PML/RARa oncoprotein is a direct molecular target of retinoic acid in acute promyelocytic leukemia cells. Blood 1996, 88:2826-2832.
38. Matikainen S, Ronni T, Hurme M, Pine R, Julkunen I: Retinoic acid activates Interferon regulatory factor-1 gene expression in myeloid cells. Blood 1996, 88:114-123.
39. Hsu CA, Rishi AK, Su-Li X, Gerald TM, Dawson Ml, Schiffer CA, Reichert U, Shroot B, Poirer GC, Fontana JA: Retinoid Induced apoptosis in leukemic cells through a retinoic acid nuclear receptor-independent pathway. Blood 1997, 89:4470-4479.
40. Munker R, Kobayashi T, Elstner E, Norman AW, Uskokovic M, Zhang W, Andreeff M, Koeffler HP: A new series of vitamin D analogs is highly active for clonal inhibition, differentiation, and induction of WAF1 in myeloid leukemia. Blood 1996, 88:2201-2209.
41. Gore SD, Miller CB, Weng LJ, Burks K, Griffith CA, Chen TL, Burke PJ, Grever M, Rowinsky EK: Improved hematopoiesis in patients with myelodysplastlc syndromes (MDS) and acute myeloid leukemia (AML) following administration of the putative differentiating agent sodium phenylbutyrate [abstract #2315]. Blood 1996, 88(suppl 1):582a.
42. Samid D, Shack S, Myers CE: Selective growth arrest and phenotypic reversion of prostate cancer cells in vitro by nontoxic pharmacologic concentrations of phenylacetate. J Clin Invest 1993, 91:2288-2295.
43. Anderson JE, Anasetti C, Appelbaum FR, Schoch G, Cooley TA, Hansen JA, Buckner CD, Sanders JE, Sullivan KM, Storb R: Unrelated donor marrow transplantation for myelodysplasla (MDS) and MDS-related acute myeloid leukaemia. Br J Haematol 1996, 93:59-67.
44. Anderson JE, Appelbaum FR, Schoch G, Cooley T, Anasetti C, Bensinger WI, Bryant E, Buckner CD, Chauncey T, Clift RA, et al.: Allogeneic marrow transplantation for myelodysplastic syndrome with advanced disease morphology: a phase II study of busulfan, cyclophosphamide, and total-body irradiation and analysis of prognostic factors. J Clin Oncol 1996, 14:220-226.
45. O'Donnell MR, Long GD, Parker PM, Niland J, Nademanee A, Amylon M, Chao N, Negrin RS, Schmidt GM, Slovak ML, et al.: Busulfan/cyclophosphamide as conditioning regimen for allogeneic bone marrow transplantation for myelodysplasia. J Clin Oncol 1995, 13:2973-2979.
46. Sutton L, Chastang C, Ribaud P, Jouet J-P, Kuentz M, Attal M, Reiffers J, Tigaud J-M, Rio B, Dauriac C, et al., for the Societe Francaise de Greffe de Moelle: Factors influencing outcome on de novo myelodysplastic syndromes treated by allogeneic bone marrow transplantation: a long term study of 71 patients. Blood 1996, 88:358-365.
47. Delforge M, Demuynck H, Vandenberghe P, Verhoef G, Zachee P, Van Duppen V, Marijnen P, Van den Berghe H, Boogaerts MA: Polyclonal primitive hematopoietic progenitors can be detected in mobilized peripheral blood from patients with high-risk myelodysplastic syndromes. Blood 1995, 86:3660-3667.
48. Demuynck H, Delforge M, Verhoef GEG, Zachee P, Vandenberghe P, Van Den Berghe H, Boogaerts MA: Feasibility of peripheral blood progenitor cell harvest and transplantation in patients with poor-risk myelodysplastic syndromes. Br J Haematol 1996, 92:351-359.